Chinese doctors say Avigan "clearly effective" in COVID-19

19 March 2020

With evidence from Chinese authorities suggesting that Avigan (favipiravir) could be effective in treating the symptoms of COVID-19, shares in the drug’s developer, Fujifilm Toyama Chemical, have surged.

Zhang Xinmin, from China’s science and technology ministry, said the drug had “a high degree of safety,” and that it was “clearly effective in treatment.”

Avigan has produced encouraging outcomes in clinical studies enrolling over 300 patients in Wuhan, the epicenter of the outbreak, as well as in Shenzhen.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Biotechnology